CX-4945: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 17 patients showed that oral CX-4945 produced 3 cases of stable disease. The MTD was 600 mg CX-4945 given 4 times daily for the first 3 consecutiv...